Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Central Nervous System NeoplasmSolid Neoplasm
Interventions
PROCEDURE

Dynamic Contrast-Enhanced Magnetic Resonance Imaging

Correlative studies

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

BIOLOGICAL

Trebananib

Given IV

Trial Locations (22)

10032

Columbia University/Herbert Irving Cancer Center, New York

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

Childrens Oncology Group, Philadelphia

20010

Children's National Medical Center, Washington D.C.

30322

Children's Healthcare of Atlanta - Egleston, Atlanta

35233

Children's Hospital of Alabama, Birmingham

University of Alabama at Birmingham Cancer Center, Birmingham

38105

St. Jude Children's Research Hospital, Memphis

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

46202

Riley Hospital for Children, Indianapolis

48109

C S Mott Children's Hospital, Ann Arbor

53226

Children¿s Hospital of Wisconsin, Milwaukee

55455

University of Minnesota/Masonic Cancer Center, Minneapolis

60611

Lurie Children's Hospital-Chicago, Chicago

63110

Washington University School of Medicine, St Louis

77030

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston

92868

Children's Hospital of Orange County, Orange

94143

UCSF Medical Center-Parnassus, San Francisco

97239

Oregon Health and Science University, Portland

98105

Seattle Children's Hospital, Seattle

M5G 1X8

Hospital for Sick Children, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01538095 - Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors | Biotech Hunter | Biotech Hunter